Excellent post in highlighting the effect of treatment of R&D on P&L in a single year however I would suggest that by focussing on past/current year PE the entire thread serves only to minimise the cumulative value of CSL's R&D spend.
To put the value of this annual R&D spend in perspective (if I am not mistaken) it is more than 5 times the cumulative annual R&D spend of MSB and PNV combined. The benefits of this (fully expensed) investment will only be seen many years after the initial spend has been made.
However the historical success of CSL gives some comfort in the likelihood of a profitable outcome from this investment. This historical R&D (and success in acquisitions) has been a secret to CSL's long term success.
So, imho it is entirely appropriate that CSL should have a higher PE than most companies due to the value of that nascent pipeline. Consequently I regard it as a highly promising Omni-biotech that happens to cover its own R&D and pay an annual dividend thank you very much.
Those who are valuing CSL purely on past and current year PE are somewhat (massively) missing the point imho.
- Forums
- ASX - By Stock
- CSL has more downside...and chat
Excellent post in highlighting the effect of treatment of R&D on...
-
-
- There are more pages in this discussion • 334 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$285.60 |
Change
-1.060(0.37%) |
Mkt cap ! $137.3B |
Open | High | Low | Value | Volume |
$285.50 | $285.86 | $282.18 | $63.81M | 224.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1298 | $317.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$257.04 | 578 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1298 | 317.520 |
4 | 4416 | 314.160 |
1 | 1170 | 310.000 |
1 | 52 | 307.300 |
2 | 16685 | 305.590 |
Price($) | Vol. | No. |
---|---|---|
257.040 | 578 | 2 |
264.180 | 2114 | 2 |
265.610 | 2389 | 2 |
267.910 | 9 | 1 |
271.320 | 57230 | 37 |
Last trade - 15.59pm 13/11/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online